A Single-dose, Open-label, Randomised, 2-way Crossover, Clinical Pharmacology Study of Four Inhalations of CHF 1535 100/6 NEXT DPI (Fixed Combination of Beclomethasone Diproponate 100 microg Plus Formoterol Fumarate 6 microg) Versus the Same Dose of CHF 1535 100/6 pMDI Both Administered With Charcoal Block.

Trial Profile

A Single-dose, Open-label, Randomised, 2-way Crossover, Clinical Pharmacology Study of Four Inhalations of CHF 1535 100/6 NEXT DPI (Fixed Combination of Beclomethasone Diproponate 100 microg Plus Formoterol Fumarate 6 microg) Versus the Same Dose of CHF 1535 100/6 pMDI Both Administered With Charcoal Block.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Beclometasone/formoterol (Primary)
  • Indications Asthma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 06 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 06 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top